Malaria biomimetic for tumor targeted drug delivery

Summary

This preclinical study borrows the placental targeting mechanism of malaria-infected red blood cells to direct chemotherapy toward cancer. The parasite protein VAR2CSA recognizes a distinctive form of chondroitin sulfate in the placenta. A similar oncofetal chondroitin sulfate is displayed by many malignant cells, creating a potential tumor marker. The researchers coated drug carriers with erythrocyte membrane and used a lipid catcher–tag system to attach recombinant VAR2CSA to the surface. These malaria-mimicking erythrocyte nanoparticles were loaded with docetaxel. In vitro, the formulation selectively targeted and killed melanoma cells expressing the relevant glycan pattern. In a melanoma xenograft, it reached tumors effectively and produced therapeutic benefit. The principal finding is that a pathogen-derived adhesion mechanism can be reconstructed on a biomimetic drug carrier to exploit a fetal-like glycan shared by cancer cells. This establishes proof of concept for tumor targeting in one melanoma model and suggests possible relevance across malignancies that present the same marker. The abstract does not quantify specificity against normal tissues, biodistribution, toxicity, survival, immune responses to recombinant VAR2CSA, or efficacy in additional cancer types.